Antag Therapeutics ApS: Financial statements 2024
CVR: 38402056
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Antag Therapeutics ApS (CVR 38402056) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -30,596,301 and a net result of DKK -32,265,249 compared with DKK -13,811,394 the year before. Equity in the 2024 report amounted to DKK 201,234,892. The solvency ratio was 89.3%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -30,596,301
- Profit/Loss
- DKK -32,265,249
- Equity
- DKK 201,234,892
- Total Assets
- DKK 225,360,878
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -30.6M | -32.3M | 201.2M | 2 |
| 2023 | - | -13.7M | -13.8M | -9.2M | 2 |
| 2022 | - | -9.9M | -9.8M | 4.6M | 2 |
| 2021 | - | -13.1M | -14.9M | 10.9M | 6 |
| 2020 | - | -10.9M | -12.4M | -9.8M | 7 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of November 5, 2024, EY Godkendt Revisionspartnerselskab has been appointed auditor of Antag Therapeutics ApS.
As of November 5, 2024, KPMG P/S has stepped down as auditor of Antag Therapeutics ApS.
As of November 5, 2024, Jørgen Søberg Petersen has joined the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Alexander Hovard Sparre-Ulrich has joined the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Amit Kantilal Shah has joined the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Alexander Volker Wilhelm Mayweg has joined the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Jens Juul Holst has left the board of directors of Antag Therapeutics ApS.
As of November 5, 2024, Pieter Jeroen Bakker has left the board of directors of Antag Therapeutics ApS.
Antag Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -13,707,565, and the net result was DKK -13,811,394.
About Antag Therapeutics ApS
Antag Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Antag Therapeutics IVS. The management consists of Philip Just Larsen. The board consists of Keith Richard Leonard Jr (chair), Alexander Volker Wilhelm Mayweg, Amit Kantilal Shah and Jørgen Søberg Petersen. The company's owners include Novo Holdings A/S, Dawn Holdco SCSp and Versant Venture Capital VII, L.P.. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -191,588,449 and a net result of DKK -200,999,582 compared with DKK -32,265,249 the year before. Equity in the 2025 report amounted to DKK 235,310.